Shopping Cart
- Remove All
Your shopping cart is currently empty
GSK-626616
🥰Excellent
Catalog No. T15422Cas No. 1025821-33-3
GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.
GSK-626616
🥰Excellent
Purity: 99.48%
Catalog No. T15422Cas No. 1025821-33-3
GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $44 | In Stock | |
| 5 mg | $97 | In Stock | |
| 10 mg | $155 | In Stock | |
| 25 mg | $296 | In Stock | |
| 50 mg | $547 | In Stock | |
| 100 mg | $789 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "GSK-626616"
GNF4877
T114472041073-22-5In house
GNF4877 is a potent inhibitor of DYRK1A and GSK3β (IC50s: 6 nM and 16 nM, respectively), resulting in the blockade of nuclear export of nuclear factor of activated T-cells (NFATc) and increased β-cell proliferation.
- $127
Size
QTY
CK2/ERK8-IN-1
TMCB
T108271085822-09-8In house
CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).
- $30
Size
QTY
YK-2-69
T695642619846-89-6In house
YK-2-69 is a highly selective DYRK2 inhibitor with anti-prostate cancer effects.
- $293
Size
QTY
Harmine
Cited
Telepathine
T1711442-51-3
Harmine (Telepathine) is an alkaloid isolated from seeds of Peganum harmala.
- $30
Size
QTY
CitedML 315
T367071440251-53-5
ML 315 is a selective Clk and DYRK inhibitor with potential anticancer activity for the study of neurological disorders.
- $44
Size
QTY
ARN25068
T613602649882-80-2In house
ARN25068 is a potent inhibitor of GSK-3β, FYN, and DYRK1A protein kinases, exerting its activity in the sub-micromolar range. This compound effectively addresses tau hyperphosphorylation [1].
- $48
Size
QTY
ML167
NCGC00188654, CID44968231
T26701285702-20-6
ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.
- $29
Size
QTY
EHT 1610
EHT 5372
T152041425945-60-3In house
EHT 1610 (EHT 5372) is a potent inhibitor of DYRK, with an IC50 of 0.36 nM and 0.59 nM for DYRK1A and DYRK1B, respectively. EHT 1610 has an inhibitory effect on leukemia, regulating cell cycle and inducing cell apoptosis.
- $88
Size
QTY
INDY
1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one
T155791169755-45-6
INDY is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B with IC50s of 0.24 μM and 0.23 μM and a Ki of 0.18 μM for Dyrk1A ATP pocket, respectively.
- $55
Size
QTY
LDN-192960
TQ0111184582-62-5
LDN-192960 is a potent inhibitor of Haspin and DYRK2 (IC50s: 10 nM and 48 nM).
- $133
Size
QTY
AZ-Dyrk1B-33
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine
T143641679330-37-0
AZ-Dyrk1B-33 (3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine) is a potent and selective Dyrk1B kinase inhibitor with an IC50 of 7 nM.
- $39
Size
QTY
Select Batch
Purity:99.48%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia. |
| Targets&IC50 | β-glucuronidase:0.7 nM |
| In vitro | GSK-626616 (serum-deprived HeLa cells) reduces EGF-induced phosphorylation of PRAS40 at Thr246. GSK-626616 enhances the binding of PRAS40 to mTORC1[2]. GSK-626616 abolishes the phosphorylation of S6K1 at Thr389 in nonstimulated HeLa cells. GSK-626616 reduces the phosphorylation of S6K1 at Thr389 in EGF- and insulin-stimulated HeLa cells, showing that mTORC1 activity is impaired[2]. |
| Molecular Weight | 401.27 |
| Formula | C18H10Cl2N4OS |
| Cas No. | 1025821-33-3 |
| Smiles | Clc1cccc(Cl)c1NC1=NC(=O)\C(S1)=C\c1ccc2nccnc2c1 |
| Relative Density. | 1.55 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 49 mg/mL (122.11 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy GSK-626616 | purchase GSK-626616 | GSK-626616 cost | order GSK-626616 | GSK-626616 chemical structure | GSK-626616 in vitro | GSK-626616 formula | GSK-626616 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.